首页> 美国卫生研究院文献>Molecular Therapy Oncolytics >Oncolytic Activity of Targeted Picornaviruses Formulated as Synthetic Infectious RNA
【2h】

Oncolytic Activity of Targeted Picornaviruses Formulated as Synthetic Infectious RNA

机译:靶向小核糖核酸病毒的溶瘤活性被公式化为合成感染性RNA。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Infectious nucleic acid has been proposed as a superior formulation for oncolytic virus therapy. Oncolytic picornaviruses can be formulated as infectious RNA (iRNA), and their unwanted tropisms eliminated by microRNA (miRNA) detargeting. However, genomic insertion of miRNA target sequences into coxsackievirus A21 (CVA21) iRNA compromised its specific infectivity, negating further development as a novel oncolytic virus formulation. To address this limitation, we substituted a muscle-specific miRNA response element for the spacer region downstream of the internal ribosomal entry site in the 5′ non-coding region of CVA21 iRNA, thereby preserving genome length while avoiding the disruption of known surrounding RNA structural elements. This new iRNA (R-CVA21) retained high specific infectivity, rapidly generating replicating miRNA-detargeted viruses following transfection in H1-HeLa cells. Further, in contrast with alternatively configured iRNAs that were tested in parallel, intratumoral administration of R-CVA21 generated a spreading oncolytic infection that was curative in treated animals without associated myotoxicity. Moreover, R-CVA21 also exhibited superior miRNA response element stability . This novel formulation is a promising agent for clinical translation.
机译:已经提出了传染性核酸作为溶瘤病毒治疗的优良制剂。溶瘤性小核糖核酸病毒可配制成感染性RNA(iRNA),并通过microRNA(miRNA)脱靶消除了它们不需要的向性。但是,将miRNA靶序列基因组插入柯萨奇病毒A21(CVA21)iRNA会损害其特异性感染性,否定了作为新型溶瘤病毒制剂的进一步发展。为了解决这一局限性,我们用肌肉特异性miRNA反应元件替代了CVA21 iRNA 5'非编码区内部核糖体进入位点下游的间隔区,从而保留了基因组长度,同时避免了对已知周围RNA结构的破坏元素。这种新的iRNA(R-CVA21)保留了高特异性感染性,在H1-HeLa细胞中转染后迅速产生了复制性miRNA靶向病毒。此外,与并行测试的交替配置的iRNA相比,R-CVA21的瘤内给药产生了扩散的溶瘤性感染,这种感染在治疗动物中可以治愈,而没有相关的肌毒性。此外,R-CVA21还表现出优异的miRNA反应元件稳定性。这种新颖的制剂是用于临床翻译的有希望的试剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号